Case Reports

Glycoprotein (GP) IIb/IIIa inhibitors are potent an-tiplatelet agents integral to the management of pa-tients with non–ST-segment elevation acute coronary syn-drome (ACS) and in the setting of percutaneous coronary intervention (PCI). However, GP IIb/IIIa inhibitor–induced thrombocytopenia can limit or complicate their use. Acute, profound thrombocytopenia is a distinct entity that was first described in patients receiving abciximab therapy.1,2 It is characterized by a precipitous decline in platelet count to <20 × 103/mm3 within 24 hours of therapy initiation.3 Al-though it generally occurs in the absence of major clinical se-quelae and responds to platelet transfusions, thrombocytope-nia can be a potentially devastating complication of therapy. We describe 3 cases of eptifibatide-associated acute, pro-found thrombocytopenia that occurred at our institution